Miyachi M, Sugimoto Y, Sugitatsu Y, Tomida A, Yoshida H, Tsuchiya K, Umebayashi D, Yamanaka T, Hashimoto N, Shishido-Hara Y, Konishi E, Iehara T. Entrectinib treatment induces a durable response against ARHGEF11::NTRK1 fusion gene-positive spinal cord diffuse pediatric-type high-grade glioma. Pediatr Blood Cancer. 2023 Jul 1.
Kawajiri T, Takeuchi H, Takahashi Y, Shimura Y, Kuroda J, Hashimoto N. Biopsy-proven Primary CNS Lymphoma in the Medulla Oblongata Presenting as Anorexia. NMC Case Rep J. 2023 May 17;10:131-137.
Fujiwara G, Okada Y, Shiomi N, Sakakibara T, Yamaki T, Hashimoto N. Derivation of Coagulation Phenotypes and the Association with Prognosis in Traumatic Brain Injury: A Cluster Analysis of Nationwide Multicenter Study. Neurocrit Care. 2023 Mar 28.
Kotani S, Murakami N, Doi T, Ogawa T, Hashimoto N. Acute epidural vertex hematoma with good hemostasis using delayed surgery after monitoring of coagulation and fibrinolytic parameters: A case report. Surg Neurol Int. 2023 Feb 24;14:73.
Sato K, Horiguchi G, Teramukai S, Yoshida T, Shimizu F, Hashimoto N. Time-of-flight magnetic resonance angiography for detection of postoperative recurrence in patients with chronic subdural hematoma. Acta Neurol Belg. 2022 Dec 7.
Okamoto T, Inoue Y, Oi Y, Taniyama I, Houri T, Teramukai S, Hashimoto N. Strategy of carotid artery stenting as first-line treatment and carotid endarterectomy for carotid artery stenosis: A single-center experience. Surg Neurol Int. 2022 Nov 4;13:513.
Fujiwara G, Murakami M, Ishii W, Maruyama D, Iizuka R, Murakami N, Hashimoto N. Effectiveness of Administration of Fibrinogen Concentrate as Prevention of Hypofibrinogenemia in Patients with Traumatic Brain Injury with a Higher Risk for Severe Hyperfibrinolysis: Single Center Before-and-After Study. Neurocrit Care. 2022 Nov 2.
Umehara T, Arita H, Miya F, Achiha T, Shofuda T, Yoshioka E, Kanematsu D, Nakagawa T, Kinoshita M, Kagawa N, Fujimoto Y, Hashimoto N, Kiyokawa H, Morii E, Tsunoda T, Kanemura Y, KIshima H. Revisiting the definition of glioma recurrence based on a phylogenetic investigation of primary and re-emerging tumor samples: a case report. Brain Tumor Pathol. 2022 Oct; 39(4):218-224.
Takeuchi H, Takahashi Y, Tanigawa S, Okamoto T, Kodama Y, Shishido-Hara Y, Yoshioka E, Shofuda T, Kanemura Y, Konishi E, Hashimoto N. Genetic Alteration May Proceed with a Histological Change in Glioblastoma: A Report from Initially Diagnosed as Nontumor Lesion Cases. NMC Case Rep J. 2022 Jul;8;9:199-208.
Yamamoto H, Nanto M, Kishida K, Goto Y, Hashimoto N. Iatrogenic Vertebral Arteriovenous Fistula Involving Brachiocephalic Vein Due to Central Venous Catheterization: A Case Report. J Endovasc Ther. 2022 Jun 23:15266028221105181.
Maruyama D, Nanto M, Hashimoto N. Response: to Letter regarding “Super-selective balloon test occlusion with electrophysiological monitoring to occlude angiographically invisible posterior communicating artery perforators with unruptured aneurysm”. Acta Neurochir(Wien). 2022 May;164(5):1309.
Fujiwara G, Okada Y, Sakakibara T, Yamaki T, Hashimoto N. The Association Between D-dimer Levels and Long-Term Neurological Outcomes of Patients with Traumatic Brain Injury : An Analysis of a Nationwide Observational Neurotrauma Database in Japan. Neurocrit Care. 2022 Apr;36(2):483-491.
Goto Y, Nanto M, Oka H, Murakami N, Nakagawa T, Kimura S, Iwamoto Y, Inoue Y, Matsumoto K, Miyamoto J, Hashimoto N. Radiological and clinical features of twig-like middle cerebral artery in comparison with moyamoya angiopathy: a multicenter retrospective study. J Neurosurg. 2022 Apr 15;137(6):1718-1726.
Uzura Y, Takeuchi H, Ashida S, Fujii C, Shishido-Hara Y, Inaba T, Takai Y, Akazawa K, Mizuno T, Hashimoto N. A tumefactive anti-MOG antibody associated disorder heralding central nervous system B-cell Lymphoma: Case report on diagnostic challenge. J Neuroimmunol. 2022 Apr 15;365:577823.
Moyama C, Fujita M, Ando S, Taniguchi K, Ii H, Tanigawa S, Hashimoto N, Nakata S. Stat5b inhibition blocks proliferation and tumorigenicity of glioblastoma stem cells derived from a de novo murine brain cancer model. Am J Cancer Res. 2022 Mar 15;12(3):1129-1142.
Maruyama D, Nanto M, Ogita S, Kishida K, Fujiwara G, Murakami M, Murakami N, Hashimoto N. Super-selective balloon test occlusion with electrophysiological monitoring to occlude angiographically invisible posterior communicating artery perforators with unruptured aneurysm. Acta Neurochir(Wien). 2022 Jan;164(1):169-172.
Yokota C, Kagawa N, Takano K, Chiba Y, Kinoshita M, Kijima N, Oji Y, Oka Y, Sugiyama H, Tsuboi A, Izumoto S, KIshima H, Hashimoto N. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy. Cancer Immunol Immunother. 2022 Jan;71(1):189-201.
Fujiwara G, Maruyama D, Okabe H, Komaru Y, Muraakami M, Katsura K, Murakami N, Hashimoto N. A case of fibromuscular dysplasia related intracerebral hemorrhage without angiographically cerebral abnormal vessels. Surg Neurol Int. 2022 Jan 20;13:26.
Tanigawa S, Fujita M, Moyama C, Ando S, Li H, Kojima Y, Fujishita T, Aoki M, Takeuchi H, Yamanaka T, Takahashi Y, Hashimoto N, Nakata S. Inhibition of Gli2 suppresses tumorigenicity in glioblastoma stem cells derived from a de novo murine brain cancer model. Cancer Gene Ther. 2021 Dec;28(12):1339-1352.
Shishido-Hara Y, Akazawa K, Takeuchi H, Hirato J, Konishi E, Yamada K, Hashimoto N. Radiologic-pathologic association of tumor-like lesions with inflammation in cerebral white matter: Comparison of two cases with distinct clinical outcomes. Neuropathology. 2021 Dec;41(6):468-475.
Umebayashi D, Nagai T, Nishii S, Hashimoto N. Posterior Surgical Techniques for Cervical Spine. No Shinkei Geka. 2021 Nov;49(6):1211-1223.
Okamoto T, Nanto M, Hasegawa Y, Goto Y, Yamamoto H, Yamanaka T, Takahashi Y, Sasajima H, Sato K, Shimizu F, Hashimoto N. Early rebleeding of a foramen magnun dural arteriovenous fistula: A case report and review of the literature. Radiol Case Rep. 2021 Sep 9;16(11):3499-3503.
Goto Y, Hino A, Hashimoto N. A comparative analysis of the modified Rankin Scale, Karnofsky Performance Status and Kurtzke expanded disability status scale in the perioperative management of patients with brainstem cavernous malformations. Clin Neurol Neurosurg. 2021 Aug;207:106785.
Fujiwara G, Okada Y, Ishii W, Iizuka R, Murakami M, Sakakibara T, Yamaki T, Hashimoto N. Association of skull fracture with in-hospital mortality in severe traumatic brain injury patients. Am J Emerg Med. 2021 Aug;46:78-83.
Nakata J, Isohashi K, Oka Y, Nakajima H, Morimoto S, Fujiki F, Oji Y, Tsuboi A, Kumanogoh A, Hashimoto N, Hatazawa J, Sugiyama H. Imaging Assessment of Tumor Response in the Era of Immunotherapy. Diagnostics(Basel). 2021 Jun 5;11(6):1041.
Aoki T, Umebayashi D, Tatsuzawa K, Hashimoto N. Symptomatic Chiari type 1 malformation associated with acromegaly : A case report. Surg Neurol Int. 2021 Jun 14;12:283.
Maruyama D, Yamada T, Murakami M, Fujiwara G, Komaru Y, Nagakane Y, Murakami N, Hashimoto N. FLAIR vascular hyperintensity with DWI for regional collateral flow and tissue fate in recanalized acute middle cerebral artery occulusion. Eur J Radiol. 2021 Feb;135:109490.
Fujiki F, Tsuboi A, Morimoto S, Hashimoto N, Inatome M, Nakajima H, Nakata J, Nishida S, Hasegawa K, Hosen N, Oka Y, Oji Y, Sogo S, Sugiyama H. Identification of two distinct populations of WT1-specific cytotoxic T Lymphocytes in co-vaccination of WT1 killer and helper peptides. Cancer Immunol Immunother. 2021 Jan;70(1):253-263.
Nagai T, Takeuchi H, Kamata K, Kawabe T, Takahashi Y, Hashimoto N. A Case of Miliary Brain Metastases Molecularly Diagnosed as Silent Lung Adenocarcinoma Origin. No Shinkei Geka. 2020 Aug;48(8):701-706.
Hashii Y, Oka Y, Kagawa N, Hashimoto N, Saitou H, Fukuya S, Kanegae M, Ikejima S, Oji Y, Ozono K, Tsuboi A, Sugiyama H. Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review. Front Oncol. 2020 Jul 24;10:1188.
Morisako T, Shishido-hara Y, Unaba T, Takeuchi H, Miyagawa-Hayashino A, Kodama Y, Takahashi Y, Konishi E, Hashimoto N. Primary CNS CD45-Depleted T-Cell Lymphoma: The First Pathologically Confirmed Case. J Neuropathol Exp Neurol. 2020 Jul 1;79(7):817-820.
Natsume A, Aoki K, Ohka F, Maeda S, Hirani M, Adilijiang A, Motomura K, Sumi M, Nishikawa R, Narita Y, Muragaki Y, Maruyama T, Ito T, Beppu T, Nakamura H, Kayama T, Sato S, Nagane M, Mishima K, Nakasu Y, Kurisu K, Yamasaki F, Sugiyama K, Onishi T, Iwadate Y, Terasaki M, Kobayashi T, Matsumura A, Ishikawa E, Sasaki H, Mukasa A, Matsuo T, Hirano H, Kumabe T, Shinoura N, Hashimoto N, Aoki T, Asai A, Abe T, Yoshino A, Arakawa Y, Asano K, Yoshimoto K, Shibui S, Okuno Y, Wakabayashi T and Members of Japan Clinical Oncology Group Brain Tumor Study Group. Genetic Analysis in Patients With Newly Diagnosed Glioblastomas Treated With Interferon-Beta Plus Temozolomide in Comparison With Temozolomide Alone. J Neurooncol. 2020 May;148(1):17-27.
Fujita T, Iwamoto Y, Takeuchi H, Tsujino H, Hashimoto N. Lumbar subdural hematoma detected after surgical treatment of chronic intracranial subdural hematoma: a case report. World Neurosurg. 2020 Feb;134:472-476.
Goto Y, Iwamoto Y, Yamamoto H, Hashimoto N. A case of hemicrania continua-tic syndrome. Neurol Clin Neurosci. 2020;00:1-3.
Tsuboi A, Hashimoto N, Fujiki F, Morimoto S, Kagawa N, Nakajima H, Hosen N, Nishida S, Nakata J, Morita S, Sakamoto J, Oji Y, Oka Y, Sugiyama H. A phase 1 clinical study of a cocktall vaccine of Wilms’ tumor 1 (WT1) HLA class Ⅰ and Ⅱpeptides for recurrent malignant glioma. Cancer Immunol Immunother. 2019 Feb;68(2):331-340.
Goto Y, Oka H, Hiraizumi S, Okamoto T, Nishii S, Yamamoto H, Yamanaka T, Nanto M, Shiomi N, Hino A, Hashimoto N. Aplastic or Twig-Like Middle Cerebral Artery Presenting with Intracerebral Hemorrhage During Pregnancy: Report of Two Cases. World Neurosurg X. 2019 Feb 5; 2:100018.
Sonoda Y, Yokoo H, Tanaka S, Kinoshita M, Nakada M, Nishihara H; committee for molecular diagnosis of the Japan Society of Brain Tumor Pathology. Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors. Brain Tumor Pathol. 2019 Apr; 36(2):56-62.
Sakata J, Sasayama T, Tanaka K, Nagashima H, Nakada M, Tanaka H, Hashimoto N, Kagawa N, Kinoshita M, Nakamizo S, Maeyama M, Nishihara M, Hosoda K, Kohmura E. MicroRNA regulating stanniocalcin-1 is a metastasis and dissemination promoting factor in glioblastoma. J Neurooncol. 2019 Apr;142(2):241-251.
Tsuboi A, Hashimoto N, Fujiki F, Morimoto S, Kagawa N, Nakajima H, Hosen N, Nishida S, Nakata J, Morita S, Sakamoto J, Oji Y, Oka Y, Sugiyama H. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunol Immunother. 2019 Feb;68(2):331-340.
Hirata T, Kinoshita M, Tamari K, Seo Y, Suzuki O, Wakai N, Achiha T, Umehara T, Arita H, Kagawa N, Kanemura Y, Shimosegawa E, Hashimoto N, Hatazawa J, Kishima H, Teshima T, Ogawa K. 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy. J Neurosurg. 2018 Sep 21: 1-11.
Goto Y, Sasajima H, Furuno Y, Kawabe T, Ohwada K, Yamanaka T, Tatsuzawa K, Hashimoto N. Unusual presentations of pediatric skull hemangiomas: report of two cases. World Neirosurg. 2018 Jul 31. Pii: S1878-8750(18)31681-4.
Kayama T, Sato S, Sakurada K, Mizusawa J, Nishikawa R, Narita Y, Sumi M, Miyakita Y, Kumabe T, Sonoda Y, Arakawa Y, Miyamoto S, Beppu T, Sugiyama K, Nakamura H, Nagane M, Nakasu Y, Hashimoto N, Terasaki M, Matsumura A, Ishikawa E, Wakabayashi T, Iwadate Y, Ohue S, Kobayashi H, Kinoshita M, Asano K, Mukasa A, Tanaka K, Asai A, Nakamura H, Abe T, Muragaki Y, Iwasaki K, Aoki T, Watanabe T, Sasaki H, Izumoto S, Mizoguchi M, Matsuo T, Takeshima H, Hayashi M, Jokura H, Mizowaki T, Shimizu E, Shirato H, Tago M, Katayama H, Fukuda H, Shibui S, and Japan Clinical Oncology Group. Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial. J Clin Oncol. 2018 Jun 20: JCO2018786186.
Takano K, Kinoshita M, Arita H, Okita Y, Chiba Y, Kagawa N, Watanabe Y, Shimosegawa E, Hatazawa J, Hashimoto N, Fujimoto Y, Kishima H. Influence of region-of-interest designs on quantitative measurement of multimodal imaging of MRnon-enhancing gliomas. Oncol Lett. 2018 May;15(5):7934-7940.
Wakabayashi T, Natsume A, Mizusawa J, Katayama H, Fukuda H, Sumi M, Nishikawa R, Narita Y, Muragaki Y, Maruyama T, Ito T, Beppu T, Nakamura H, Kayama T, Sato S, Nagane M, Mishima K, Nakasu Y, Kurisu K, Yamasaki F, Sugiyama K, Onishi T, Iwadate Y, Terasaki M, Kobayashi H, Matsumura A, Ishikawa E, Sasaki H, Mukasa A, Matsuo T, Hirano H, KUmabe T, Shinoura N, Hashimoto N, Aoki T, Asai A, Abe T, Yoshino A, Arakawa Y, Asano K, Yoshimoto K, Shinobui S: JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. J Neurooncol. 2018 Jul;138(3):627-636.
Takahashi Y, Nishio A, Yamamoto D, Kamada H, Hashimoto N: Usefulness of 18F-fluorodeoxyglucose-Positron Emission Tomography in Comparison with Methionine-Positron Emission Tomography in Differentiating Solid Hemangioblastoma from Aduly Cerebellar Tumors. World Neurosurg. 2018 Feb;110:e648-e652.
Hirayama R, Kinoshita M, Arita H, Kagawa N, Kishima H, Hashimoto N, Fujimoto Y, Yoshimine T. Voxel-based lesion mapping of meningioma: a comprehensive lesion location mapping of 260 lesions. J Neurosurg. 2017 Sep 1:1-6.
Wakabayashi T, Iuchi T, Tsuyuguchi N, Nishikawa R, Arakawa Y, Sasayama T, Miyake K, Narita Y, Hashimoto N, Okuda O, Matsuda H, Kubota K, Ito K, Nakazato Y, Kubomura K. Diagnostic Performance and Safety of Positron Emission Tomography Using (18)F-Fluciclovine in Patients with Clinically Suspected High- or Low-grade Gliomas: A Multicenter Phase IIb Trial. Asia Ocean J Nucl Med Biol. 2017 Winter ;5(1):10-21.
Takahashi Y, Sawada T, Akahane T, Kawase Y, Ikeda H, Makino K, Nakamura H, Hide T, Yano S, Hashimoto N, Kamada H. Monocyte chemoattractant protein 1 expression and proliferation in primary central nervous system lymphoma. Oncol Lett. 2017 Jul;14(1):264-270.
Goto Y, Furuno Y, Kawabe T, Ohwada K, Tatsuzawa K, Sasajima H, Hashimoto N. Treatment of a skull-base giant cell tumor with endoscopic endonasal resection and denosumab: case report. J Neurosurg. 2017 Feb;126(2):431-434.
Takashima S, Oka Y, Fujiki F, Morimoto S, Nakajima H, Nakae Y, Nakata S, Hosen N, Tatsumi N, Mizuguchi K, Hashimoto N, Oji Y, Tsuboi A, Kumanogoh A, Sugiyama H. Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine. Future Sci OA. 2016 Oct 3;2(4):FSO96.
Kawabe T, Yamamoto M, Sato Y, Yomo S, Kondoh T, Nagano O, Serizawa T, Tsugawa T, Okamoto H, Akabane A, Aita K, Sato M, Jokura H, Kawagishi J, Shuto T, Kawai H, Moriki A, Kenai H, Iwai Y, Gondo M, Hasegawa T, Yasuda S, Kikuchi Y, Nagatomo Y, Watanabe S, Hashimoto N. Gamma Knife radiosurgery for brain metastases from pulmonary large cell neuroendocrine carcinoma: a Japanese multi-institutional cooperative study(JLGK1401). J Neurosurg. 2016 Dec;125(Suppl 1):11-17.
Kinoshita M, Sakai M, Arita H, Shofuda T, Chiba Y, Kagawa N, Watanabe Y, Hashimoto N, Fujimoto Y, Yoshimine T, Nakanishi K, Kanemura Y. Introduction of High Throughput Magnetic Resonance T2-Weighted Image Texture Analysis for WHO Grade 2 and 3 Gliomas. PLoS One. 2016 Oct 7;11(10):e0164268.
Kijima N, Hashimoto N, Chiba Y, Fujimoto Y, Sugiyama H, Yoshimine T. Functional Roles of Wilms’ Tumor 1(WT1) in Malignant Brain Tumors. Codon Publications; 2016 Mar. Capter15.
Oji Y, Hashimoto N, Tsuboi A, Murakami Y, Iwai M, Kagawa N, Chiba Y, Izumoto S, Elisseeva O, Ichinohasama R, Sakamoto J, Morita S, Nakajima H, Takashima S, Nakase Y, Nakata J, Kawakami M, Nishida S, Hosen N, Fujiki F, Morimoto S, Adachi M, Iwamoto M, Oka Y, Yoshimine T, Sugiyama H. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. Int J Cancer. 2016 Sep; 139(6): 1391-401.
Hashimoto N. Cancer Immunotherapy for Gliomas: Overview and Future Directions. Neurol Med Chir (Tokyo). 2016 Jul 15;56(7):355-60.
Hino A, Oka H, Hashimoto Y, Echigo T, Koseki H, Fujii A, Katsumori T, Shiomi N, Nozaki K, Arima H, Hashimoto N. Direct Microsurgical Embolectomy for Acute Occlusion of the Internal Carotid Artery and Middle Cerebral Artery. World Neurosurg. 2016 Apr ;88:243-51.
Kinoshita M, Arita H, Okita Y, Kagawa N, Kishima H, Hashimoto N, Tanaka H, Watanabe Y, Shimosegawa E, Hatazawa J, Fujimoto Y, Yoshimine T. Comparison of diffusion tensor imaging and (11)C-methionine positron emission tomography for reliable prediction of tumor cell density in gliomas. J Neurosurg. 2016 Nov ;125(5):1136-1142.
Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyazaki Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun. 2016 Aug 8; 4(1): 79.
Takano K, Kinoshita M, Takagaki M, Sakai M, Tateishi S, Achiha T, Hirayama R, Nishino K, Uchida J, Kumagai T, Okami J, Kawaguchi A, Hashimoto N, Nakanishi K, Imamura F, Higashiyama M, Yoshimine T. Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor. Neuro Oncol. 2016 May ;8(5):716-24.
Shiomi N, Echigo T, Hino A, Hashimoto N, Yamaki T. Criteria for CT and Initial Management of Head Injured Infants: A Review. Neurol Med Chir (Tokyo). 2016 Jul;56(7): 442-8.
Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AAN, Giannini C, Li KKW, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DCY, Seow WT, Chang KTE, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fèvre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobágyi T, Klekner A, László B, Pócza T, Hauser P, Schüller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen MC, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, López-Aguilar E, Lyden D, Garzia L, Shih DJH, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DTW, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016 Apr;17(4):484-95.
Takano K, Kinoshita M, Arita H, Okita Y, Chiba Y, Kagawa N, Fujimoto Y, Kishima H, Kanemura Y, Nonaka M, Nakajima S, Shimosegawa E, Hatazawa J, Hashimoto N, Yoshimine T. Diagnostic and Prognostic Value of 11C-Methionine PET for Nonenhancing Gliomas. AJNR Am J Neuroradiol. 2016 Jan;37(1):44-50.
Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H, Kubo A, Shuto T, Ohno M, Miyakita Y, Kocialkowski S, Sasayama T, Hashimoto N, Maehara T, Shibui S, Ushijima T, Kawahara N, Narita Y, Ichimura K. Recurrent mutations of CD79B and MYD88 are hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobaiol. 2016 Apr;42(3):279-90.
Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Heroid-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neurooncology: a report of the RANO working group. Lancet Oncol. 2015 Nov ;16(15):e534-542.
Horiike H, Murata I, Iida T, Yoshihashi S, Hoashi E, Kato I, Hashimoto N, Kuri S, Oshiro S. Liquid Li based neutron source for BNCT and science application. Appl Radiat Isot. 2015 Dec;106:92-4.
Hashimoto N, Tsuboi A, Kagawa N, Chiba Y, Izumoto S, Kinoshita M, Kijima N, Oka Y, Motimoto S, Nakajima H, Morita S, Sakamoto J, Nishida S, Hosen N, Oji Y, Arita N, Yoshimine T, Sugiyama H. Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. Cancer Immunol Immunother. 2015 Jun ;64(6): 707-716.
Kinoshita M, Taniguchi M, Takagaki M, Seike N, Hashimoto N, Yoshimine T. Development of a non-tissue adherent neurosurgical patty and an ex vivo testing system to evaluate adherent characteristics. J Neurosurg. 2015 May ;122(5):1180-4.
Tamari K, Suzuki O, Hashimoto N, Kagawa N, Fujiwara M, Sumida I, Seo Y, Isohashi F, Yoshioka Y, Yoshimine T, Ogawa K. Treatment outcomes using Cyber Knife for brain metastases from lung cancer. J Radiat Res. 2015 Jan ;56(1):151-8.
Arita H, Narita Y, Yoshida A, Hashimoto N, Yoshimine T, Ichimura K. IDH1/2 mutation detection in gliomas. Brain Tumor Pathol. 2015 Apr ;32(2):79-89.
Hashimoto N, Kagawa N, Arita H, Tsuboi A, Oka Y, Oji Y, Sugiyama H, Yoshimine T. Ⅲ. Peptide vaccination therapy against brain tumors. Gan To Kagaku Ryoho. 2015 Jun;42(6):687-9.
Furuno Y, Sasajima H. Medical comics as tools to aid in obtaining informed consent for stroke care. Medicine (Baltimore). 94(26)e1077, 2015.
橋本直哉, 香川尚己, 有田英之, 坪井昭博, 岡芳弘, 尾路祐介, 杉山治夫, 吉峰俊樹. Central Nervous System Tumor:Glioma 脳腫瘍 グリオーマ 脳腫瘍に対するペプチドワクチン療法. 癌と化学療法42(6) : 687-689, 2015.
2014年
Tanaka M, Fujimoto Y, Hirayama R, Chiba Y, Hashimoto N, Yoshimine T. Clinical and radiological features of endodermal cyst of the oculomotor nerve: A case report. Br J Neurosurg. 2014 Sep;15:1-2. [Epub ahead of print]
Kinoshita M, Sasayama T, Narita Y, Yamashita F, Kawaguchi A, Chiba Y, Kagawa N, Tanaka K, Kohmura E, Arita H, Okita Y, Ohno M, Miyakita Y, Shibui S, Hashimoto N, Yoshimine T. Different spatial distribution between germinal center B and non-germinal center B primary central nervous system lymphoma revealed by magnetic resonance group analysis. Neuro Oncol. 2014 May;16(5):728-734.
Kijima N, Hosen N, Kagawa N, Hashimoto N, Kinoshita M, Oji Y, Sugiyama H, Yoshimine T. Wilm’s Tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferatuin and apoptosis. Anticancer Res. 2014 Jan;34(1):61-7.
Takahashi Y, Hashimoto N, Tokoroyama H, Yamauchi S, Nakasato M, Kondo K, Nitta K, Ide W, Hashimoto I, Kamada H. Reversible Splenial Lesion in Postpartum Cerebral Angiopathy: A Case Report. J Neuroimaging. 2014 May-Jun;24(3):292-4.
Furuno Y, Sasajima H, Goto Y, Taniyama I, Aita K, Owada K, Tatsuzawa K, Mineura K. Strategies to prevent positioning-related complications associated with the lateral suboccipital approach. J Neurol Surg B Skull Base. 75(1)35-40, 2014.
Watanabe S, Yamamoto M, Sato Y, Kawabe T, Higuchi Y, Kasuya H, Yamamoto T, Matsumura A, Barfod BE. Stereotactic radiosurgery for brain metastases: a case-matched study comparing treatment results for patients 80 years of age or older versus patients 65-79 years of age. J Neurosurg. 121(5)1148-57, 2014.
Momose T, Nariai T, Kawabe T, Inaji M, Tanaka Y, Watanabe S, Maehara T, Oda K, Ishii K, Ishiwata K, Yamamoto M. Clinical benefit of 11C methionine PET imaging as a planning modality for radiosurgery of previously irradiated recurrent brain metastases. Clin Nucl Med. 39(11)939-43, 2014.
Yamamoto M, Kawabe T, Higuchi Y, Sato Y, Nariai T, Watanabe S, Barfod BE, Kasuya H. Validity of prognostic grading indices for brain metastasis patients undergoing repeat radiosurgery. World Neurosurg. 82(6)1242-9, 2014.
Yamamoto M, Kawabe T, Sato Y, Higuchi Y, Nariai T, Watanabe S, Kasuya H. Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors. J Neurosurg. 121(Suppl)16-25, 2014.
Morimoto M, Yoshioka Y, Kotsuma T, Adachi K, Shiomi H, Suzuki O, Seo Y, Koizumi M, Kagawa N, Kinoshita M, Hashimoto N, Ogawa K. Hypofractionated stereotactic radiation therapy in three to five fractions for vestibular schwannoma. Jpn J Clin Oncol. 2013 Aug;43(8):805-12.
Hirayama R, Fujimoto Y, Umegaki M, Kagawa N, Kinoshita M, Hashimoto N, Yoshimine T. Training to acquire psychomotor skills for endoscopic endonasal surgery using a personal webcam trainer. J Neurosurg. 2013 May;118(5):1120-1126.
Nomura K, Kazui H, Tokunaga H, Hirata M, Goto T, Goto Y, Hashimoto N, Yoshimine T, Takeda M. Possible roles of the dominant uncinate fasciculus in naming objects: A case report of intraoperative electrical stimulation on a patient with a brain tumour. Behav Neurol. 2013;27(2): 229-34.
Khoo HM, Kishima H, Kinoshita M, Goto Y, Kagawa N, Hashimoto N, Maruno M, Yoshimine T. Radiation-induced anaplastic ependymoma with a remarkable clinical response to temozolomide: A case report. Br J Neurosurg. 2013 Apr;27(2):259-61.
Yamamoto M, Kawabe T, Higuchi Y, Sato Y, Nariai T, Barfod BE, Kasuya H, Urakawa Y. Delayed complications in patients surviving at least 3 years after stereotactic radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 85(1)53-60, 2013.
Yamamoto M, Serizawa T, Sato Y, Kawabe T, Higuchi Y, Nagano O, Barfod BE, Ono J, Kasuya H, Urakawa Y. Validity of two recently-proposed prognostic grading indices for lung, gastro-intestinal, breast and renal cell cancer patients with radiosurgically-treated brain metastases. J Neurooncol. 111(3)327-35, 2013.
Yamamoto M, Kawabe T, Sato Y, Higuchi Y, Nariai T, Barfod BE, Kasuya H, Urakawa Y. A case-matched study of stereotactic radiosurgery for patients with multiple brain metastases: comparing treatment results for 1-4 vs ≥ 5 tumors: clinical article. J Neurosurg. 118(6)1258-68, 2013.